Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pedro Cahn

Showing results (101-110 of 207) with videos related to

Pageof 21
Sort By:
Plos One|August 13, 2013
Routine HIV testing among hospitalized patients in Argentina. is it time for a policy change?María Eugenia Socías, Laura Hermida, Mariana Singman, et al.
Antiviral Therapy|April 29, 2022
Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studiesJean Michel Molina, Luminita Ene, Pedro Cahn, et al.
The Journal of General Virology|October 22, 2008
Lack of viral selection in human immunodeficiency virus type 1 mother-to-child transmission with primary infection during late pregnancy and/or breastfeedingAna Ceballos, Guadalupe Andreani, Chiara Ripamonti, et al.
NPJ Biofilms and Microbiomes|July 12, 2023
Oral and anal microbiome from HIV-exposed individuals: role of host-associated factors in taxa composition and metabolic pathwaysEzequiel Lacunza, Valeria Fink, María E Salas, et al.
Current Medical Research and Opinion|July 22, 2004
Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014)Asda Vibhagool, Pedro Cahn, Mauro Schechter, et al.
Journal of the International AIDS Society|November 14, 2014
Changes in lipid levels after 48 weeks of dual versus triple therapy observed in the GARDEL studyPedro Cahn, Jaime Andrade Villanueva, Jose Arribas, et al.
Pathogens & Immunity|January 6, 2022
Pre-cART Immune Parameters in People Living With HIV Might Help Predict CD8+ T-Cell Characteristics, Inflammation Levels, and Reservoir Composition After Effective cARTJimena Salido, Alejandro Czernikier, César Trifone, et al.
Lancet (London, England)|July 19, 2011
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trialJean-Michel Molina, Pedro Cahn, Beatriz Grinsztejn, et al.
Antiviral Therapy|December 7, 2016
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trialMelanie Thompson, Jacob P Lalezari, Richard Kaplan, et al.
Lancet (London, England)|August 8, 2006
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trialsCharles B Hicks, Pedro Cahn, David A Cooper, et al.
Pageof 21

Showing results (101-110 of 207) with videos related to

Sort By:
Pageof 21
Plos One|August 13, 2013
Routine HIV testing among hospitalized patients in Argentina. is it time for a policy change?María Eugenia Socías, Laura Hermida, Mariana Singman, et al.
Antiviral Therapy|April 29, 2022
Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studiesJean Michel Molina, Luminita Ene, Pedro Cahn, et al.
The Journal of General Virology|October 22, 2008
Lack of viral selection in human immunodeficiency virus type 1 mother-to-child transmission with primary infection during late pregnancy and/or breastfeedingAna Ceballos, Guadalupe Andreani, Chiara Ripamonti, et al.
NPJ Biofilms and Microbiomes|July 12, 2023
Oral and anal microbiome from HIV-exposed individuals: role of host-associated factors in taxa composition and metabolic pathwaysEzequiel Lacunza, Valeria Fink, María E Salas, et al.
Current Medical Research and Opinion|July 22, 2004
Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014)Asda Vibhagool, Pedro Cahn, Mauro Schechter, et al.
Journal of the International AIDS Society|November 14, 2014
Changes in lipid levels after 48 weeks of dual versus triple therapy observed in the GARDEL studyPedro Cahn, Jaime Andrade Villanueva, Jose Arribas, et al.
Pathogens & Immunity|January 6, 2022
Pre-cART Immune Parameters in People Living With HIV Might Help Predict CD8+ T-Cell Characteristics, Inflammation Levels, and Reservoir Composition After Effective cARTJimena Salido, Alejandro Czernikier, César Trifone, et al.
Lancet (London, England)|July 19, 2011
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trialJean-Michel Molina, Pedro Cahn, Beatriz Grinsztejn, et al.
Antiviral Therapy|December 7, 2016
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trialMelanie Thompson, Jacob P Lalezari, Richard Kaplan, et al.
Lancet (London, England)|August 8, 2006
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trialsCharles B Hicks, Pedro Cahn, David A Cooper, et al.
Pageof 21